---
title: "Design Therapeutics Q2 FY26 net loss widens to $20.2 million; R&D expenses rise to $16.4 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294690302.md"
description: "Design Therapeutics reported a widened Q2 FY26 net loss of $20.2 million, up from $19.1 million year-over-year, driven by increased R&D expenses of $16.4 million. Cash reserves decreased to $207.4 million. The RESTORE-FA trial maintains 1 mpk as the go-forward dose, with 12-week data expected in Q1 2027. Additionally, four-week data showed DT-216P2 increased endogenous frataxin, and Phase 1 MAD trials for DT-818 in DM1 have begun."
datetime: "2026-08-03T12:06:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294690302.md)
  - [en](https://longbridge.com/en/news/294690302.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294690302.md)
---

# Design Therapeutics Q2 FY26 net loss widens to $20.2 million; R&D expenses rise to $16.4 million

-   Design Therapeutics posted a Q2 net loss of USD 20.2 million, widening from USD 19.1 million a year earlier. \* R&D expenses rose to USD 16.4 million from USD 15.7 million, while G&A expenses edged down to USD 5.8 million from USD 5.83 million. \* Cash, cash equivalents and investment securities slipped to USD 207.4 million at June 30 from USD 219.8 million at Dec. 31. \* RESTORE-FA trial modifications keep 1 mpk as the planned go-forward dose, targeting 10 patients in the 12-week cohort; 12-week data are expected in Q1 2027. \* Management said four-week RESTORE-FA data showed DT-216P2 increased endogenous frataxin; dosing began in a Phase 1 MAD trial of DT-818 in DM1. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030800PRIMZONEFULLFEED9802237) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [DSGN.US](https://longbridge.com/en/quote/DSGN.US.md)

## Related News & Research

- [Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP](https://longbridge.com/en/news/295624980.md)
- [Design Therapeutics begins Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 patients](https://longbridge.com/en/news/291279515.md)
- [Dynatrace (DT) Could Be 36% Undervalued Following AI Demand And Mixed Guidance](https://longbridge.com/en/news/295659304.md)
- [Why Dynatrace (DT) Is Up 9.9% After Mixed Q1, AI Launches, And Buyback Update](https://longbridge.com/en/news/295442039.md)
- [Magle Chemoswed Holding advances Q2 interim report publication](https://longbridge.com/en/news/295568850.md)